Status Awaiting development
Technology type Medicine
Decision None selected
Process STA
ID number 4002

Provisional Schedule

Committee meeting: 1 10 November 2022
Expected publication 01 February 2023

Project Team

Project lead Jeremy Powell

Email enquiries

Stakeholders

Companies sponsors Bayer
Others Department of Health and Social Care
  NHS England
  NHS Bracknell and Ascot CCG
  NHS South Devon and Torbay CCG
  Welsh Government
Patient carer groups Black Health Agency for Equality
  Bowel Cancer Information
  Bowel Cancer UK
  Cancer Black Care
  Cancer Equality
  Cancer 52
  Crohn’s and Colitis UK
  Colostomy Association
  Guts UK
  Helen Rollason Heal Cancer Charity
  IA: Ileostomy and Internal Pouch Group
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Oesophageal Patients Association
  Pelican Cancer Foundation
  Sarcoma UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  Association of Coloproctology of Great Britain and Ireland
  Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Sarcoma Group
  British Society of Gastroenterology
  Cancer Research UK
  Primary Care Society for Gastroenterology
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Assessment group Kleijnen Systematic Reviews Ltd
Comparator companies Accord Healthcare (irinotecan and oxaliplatin)
  Almirall (fluorouracil)
  Hospira UK (fluorouracil, irinotecan, oxaliplatin and raltitrexed)
  medac GmbH (fluorouracil, folinic acid, irinotecan and oxaliplatin)
  Pfizer (irinotecan)
  Seacross Pharmaceuticals (irinotecan and oxaliplatin)
  Servier Laboratories (trifluridine–tipiracil)
  Sun Pharmaceuticals (irinotecan and oxaliplatin)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Scottish Sarcoma Network
  Scottish Society of Gastroenterology
  Welsh Health Specialised Services Committee
Relevant research groups Bowel Research UK
  Cochrane UK
  Cochrane Upper Gastrointestinal and Pancreatic Diseases Group
  Foundation for Liver research
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
25 March 2022 Invitation to participate
17 February 2022 - 10 March 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 February 2022 Draft scope documents
24 December 2021 Following a request received from the company, NICE will be undertaking an appraisal of Regorafenib for previously treated metastatic colorectal cancer. This was originally terminated guidance TA334. The appraisal is expected to start during January 2022 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during mid-March 2022. The deadline for submissions is expected in approximately late-May 2022.

For further information on our processes and methods, please see our CHTE processes and methods manual